04
Jun
Serum Institute of India has sought indemnity protection against prosecution arising from any adverse effects for people taking its Covishield vaccine. The Centre, which has come under severe criticism for the slow progress of inoculation, expects to vaccinate one billion people by the end of this calendar year. Niti Aayog member (health) V. K. Paul had recently said that Pfizer’s Covid-19 vaccine is likely to be available in India from July. The pharma giant could supply around 5 crore doses between July and October, but it has harped on indemnity as a major requirement. Mumbai-based firm Cipla, which is looking…